title: Intradermal fractional dose inactivated polio vaccine: a review of the literature.
abstract: Oral polio vaccine (OPV) will likely be insufficient to completely eradicate polio due to its propensity to mutate into neurovirulent forms and its inability to produce adequate immunity in certain areas of the world. Inactivated polio vaccine (IPV), a killed vaccine which therefore cannot mutate, may be more effective than OPV in certain populations, and will likely be required for global polio eradication. However, the high cost of IPV is prohibitive in many areas of the world. Intradermal administration has the potential to lower the dose, and thus the cost, of IPV. This article reviews the clinical studies to date on intradermal fractional dose polio vaccination. We conclude that intradermal IPV vaccination shows potential as a means to reduce the cost and increase the ease of administration of IPV, but that additional research is needed to determine the optimal fractional dose, timing, and role of adjuvants in intradermal IPV vaccination as well as the clinical significance of different antibody titers above the threshold for seroconversion.
authors.affiliation: Stanford University School of Medicine, Stanford, CA, USA. ksnelson@stanford.edu
authors.forename: Katherine S
authors.initials: KS
authors.lastname: Nelson
authors.forename: Julia M
authors.initials: JM
authors.lastname: Janssen
authors.forename: Stephanie B
authors.initials: SB
authors.lastname: Troy
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Maldonado
mesh_terms: D006801:Humans; D007271:Injections, Intradermal; D011051:Poliomyelitis / Q000517:prevention & control*; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology*; D014611:Vaccination / Q000191:economics* / Q000379:methods*
chemical_list: D011054:Poliovirus Vaccine, Inactivated